Mersana Therapeutics, Inc. (NASDAQ:MRSN) CEO Martin H. Jr. Huber Sells 50,423 Shares of Stock

Mersana Therapeutics, Inc. (NASDAQ:MRSN) CEO Martin H. Jr. Huber sold 50,423 shares of the business’s stock in a transaction that occurred on Thursday, September 12th. The stock was sold at an average price of $1.76, for a total value of $88,744.48. Following the sale, the chief executive officer now owns 116,327 shares of the company’s stock, valued at approximately $204,735.52. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Mersana Therapeutics Stock Performance

NASDAQ:MRSN opened at $2.11 on Friday. The company has a market cap of $258.85 million, a price-to-earnings ratio of -1.85 and a beta of 1.47. Mersana Therapeutics, Inc. has a fifty-two week low of $1.07 and a fifty-two week high of $6.28. The company has a debt-to-equity ratio of 2.02, a quick ratio of 2.72 and a current ratio of 2.72. The stock has a fifty day moving average price of $1.71 and a 200-day moving average price of $2.81.

Mersana Therapeutics (NASDAQ:MRSN) last posted its quarterly earnings results on Tuesday, August 13th. The company reported ($0.20) EPS for the quarter, missing analysts’ consensus estimates of ($0.17) by ($0.03). The company had revenue of $2.30 million during the quarter, compared to analyst estimates of $8.72 million. Mersana Therapeutics had a negative net margin of 349.98% and a negative return on equity of 333.91%. The firm’s revenue for the quarter was down 78.3% compared to the same quarter last year. During the same period last year, the firm earned ($0.47) EPS. As a group, equities analysts anticipate that Mersana Therapeutics, Inc. will post -0.72 EPS for the current fiscal year.

Institutional Trading of Mersana Therapeutics

Institutional investors and hedge funds have recently made changes to their positions in the company. Victory Capital Management Inc. bought a new position in Mersana Therapeutics in the fourth quarter valued at approximately $30,000. Foundations Investment Advisors LLC acquired a new stake in shares of Mersana Therapeutics in the 4th quarter valued at $237,000. Mirae Asset Global Investments Co. Ltd. acquired a new stake in shares of Mersana Therapeutics in the 1st quarter valued at $226,000. BNP Paribas Financial Markets increased its stake in shares of Mersana Therapeutics by 90.0% in the 1st quarter. BNP Paribas Financial Markets now owns 80,735 shares of the company’s stock valued at $362,000 after purchasing an additional 38,239 shares during the last quarter. Finally, ClariVest Asset Management LLC acquired a new position in shares of Mersana Therapeutics during the 1st quarter worth $2,114,000. Institutional investors own 93.92% of the company’s stock.

Wall Street Analyst Weigh In

Several research firms recently issued reports on MRSN. Lifesci Capital upgraded Mersana Therapeutics to a “strong-buy” rating in a research note on Monday, July 29th. Robert W. Baird reduced their target price on shares of Mersana Therapeutics from $4.00 to $3.00 and set a “neutral” rating for the company in a research report on Wednesday, August 14th. Finally, Citigroup decreased their price target on shares of Mersana Therapeutics from $6.00 to $5.00 and set a “buy” rating on the stock in a research note on Tuesday, August 27th. Two research analysts have rated the stock with a hold rating, five have assigned a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $6.00.

Mersana Therapeutics Company Profile

Mersana Therapeutics, Inc, a clinical stage biopharmaceutical company, develops antibody drug conjugates (ADC) for cancer patients with unmet needs. The company develops XMT-1660, a B7-H4-targeted Dolasynthen ADC candidate; and XMT-2056, an immunosynthen ADC. It has research and development collaborations with Janssen Biotech, Inc, Ares Trading SA, Merck KGaA, and Asana BioSciences, LLC for the development of ADC product candidates.